Of the 47 established BL cell lines, 3 (6 %) had p14ARF loss by homozygous deletion of CDKN2A. When Lindström et al. assessed the 7 BL cell lines with wild type TP53, 3/3 BL lines with homozygous CDKN2A deletion were EBV negative, while all 4 with retained CDKN2A were EBV positive [72]. The gene discussed is TP53; the disease is Burkitt lymphoma.